Merck isn’t placing all of its oncology bets on Keytruda (pembrolizmab). Last month, the pharma showed how much interest it had in targeted drugs called kinase inhibitors when it spent $2.7 billion to snatch up ArQule.
Today’s announcement of a $50 million collaboration with Astex and Taiho represents a much smaller ante. The collaboration covers preclinical research on small molecule agents targeting cancer-related mutations being conducted by all three companies. This includes the KRAS oncogene, once thought to be an undruggable target.
Interest in inhibiting KRAS has heightened over the past year as Amgen has revealed data from its leading candidate, called AMG 510, which is now in Phase 1/2 study along with Mirati’s MRTX849. Eli Lilly and J&J have initiated early trials of their drugs LY3499446 and JNJ-74699157, respectively.
Merck’s interest in KRAS inhibition is a sign that it believes its biological agent Keytruda, which was on track to hit $11 billion in sales in 2019, could be vulnerable to competition in diseases like lung cancer.
Last month, it released exploratory data from the KEYNOTE-042 trial indicating that in previously untreated patients with non-squamous non-small cell lung cancer (NSCLC) that expresses Keytruda’s target, called PD-1, the immuno-oncology drug alone was able to shrink tumors and delay death or disease progression in KRAS-positive patients better than chemotherapy. The finding prompted Cantor Fitzgerald analyst Louise Chen to say KRAS could “fade like a fad” if the data is confirmed in additional clinical study.
Merck doesn’t seem to think it can ignore targeted KRAS agents, however. Having its own KRAS-targeting drug could serve to secure its leading place in lung cancer, where AMG 510 and MRTX849 have been able to shrink or eliminate tumors in patients.
In Astex, the New Jersey-based big pharma found a partner that has already had some discovery success. Its research led to the successful launch of Novartis’ breast cancer drug Kisqali (ribociclib) and Johnson & Johnson’s urothelial cancer drug Balversa (erdafitinib).
By Jonathan Gardner
Source: Biopharma Dive
The Serum Institute of India (SII) expects to soon receive World Health Organisation (WHO) emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, produced for mid and low-income countries.
According to the deal, Sanofi will gain full global rights to Kymab’s fully human monoclonal antibody, KY1005 that attaches to OX40-Ligand and can potentially treat various immune-mediated diseases and inflammatory ailments.
Moderna tapped veteran Amgen executive Corinne Le Goff to spearhead that effort as chief commercial officer.